Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesdopetam (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Acronyms PD-LIDs
Sponsors Integrative Research Laboratories

Most Recent Events

27 Feb 2025 According to IRLAB Therapeutics AB Media release, data from this trial published in the Movement Disorders Clinical Practice.
27 Feb 2025 Results published in the IRLAB Media Release
28 Aug 2023 According to a IRLAB media release, results from this trial were presented at the International Congress of Parkinson's Disease and Movement Disorders, MDS Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com